《上市公司治理准则》、 《陕西盘龙药业集团股份有限公司公司章程》（以下简称"公司章程"）等规定， 公司董事会下设董事会可持续战略发展委员会，并制定本实施细则。 陕西盘龙药业集团股份有限公司董事会可持续战略发展委员会实施细则 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规 划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质 量，完善公司治理结构，根据《中华人民共和国公司法》、 第二条 董事会可持续战略发展委员会是董事会按照股东会决议设置的专 门工作机构，主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 可持续战略发展委员会由三名董事组成，其中应至少包括一名独立 董事。 第四条 可持续战略发展委员会委员由董事长、二分之一以上独立董事或者 全体董事的三分之一提名，并由董事会选举产生。 第五条 可持续战略发展委员会设主任委员一名，负责主持可持续战略发展 委员会工作，由委员选举产生，并报董事会备案。 第六条 可持续战略发展委员会任期与董事会任期一致，委员任期届满，连 选可以 ...

General Principles - The rules are established to strengthen the management of shares held by directors and senior management of Shaanxi Panlong Pharmaceutical Group Co., Ltd. and to maintain market order [1] - The rules are based on relevant laws and regulations including the Company Law and Securities Law of the People's Republic of China [1] Share Management - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or during investigations related to securities violations [3] - The maximum amount of shares that can be transferred by directors and senior management in a year is limited to 25% of their total holdings, with exceptions for certain circumstances [4] - Newly acquired shares can only be transferred at a rate of 25% in the year they are acquired, and any increase in shares due to company actions will proportionally increase the transferable amount [4] Disclosure Requirements - Directors and senior management must report their share transactions to the company and disclose relevant information to the stock exchange within two trading days of any change [12] - A detailed plan must be disclosed prior to any share reduction, including the number of shares, time frame, and reasons for the reduction [5][7] - Any shareholding changes due to court-ordered transactions must be disclosed within two trading days of receiving the execution notice [6] Additional Regulations - Directors and senior management must ensure that their immediate family members and related parties do not engage in insider trading [24] - The rules apply to various scenarios including share increases due to capital increases or stock options [18] - The company is responsible for ensuring the accuracy and timeliness of the reported data [25]

陕西盘龙药业集团股份有限公司总裁工作细则 指引第 1 号—主板上市公司规范运作》、《陕西盘龙药业集团股份有限公司章程》 （以下简称"公司章程"）的有关规定，制定本细则。 第二条 公司依法设置总裁。 第三条 总裁由董事会聘任或者解聘，对董事会负责，根据公司章程的规定 或者董事会的授权行使职权。总裁列席董事会会议。 第四条 总裁主持公司日常生产经营和管理工作，组织实施董事会决议。 第二章 总裁的任职资格与任免程序 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 按照建立现代企业制度的要求，进一步完善陕西盘龙药业集团股份 有限公司（以下简称"公司"或"本公司"）治理结构，根据《中华人民共和国 公司法》、 《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管 第五条 总裁应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营 管理能力； （二）具有调动员工积极性、建立合理的组织机构、协调各种内外关系和统 揽全局的能力； （三）具有一定年限的企业管理或经济工作经历，精通本行业、熟悉多种行 业的生产经营业务和掌握国家有关政策、法律、法规； （四） ...

Core Viewpoint - The internal audit management system of Shaanxi Panlong Pharmaceutical Group Co., Ltd. aims to enhance internal audit work, reduce decision-making risks, improve economic efficiency, and ensure healthy business operations in accordance with relevant laws and regulations [1][2]. Group 1: General Principles - The internal audit management system is established based on the Audit Law of the People's Republic of China and other regulatory guidelines to strengthen internal audit work [1]. - The audited entities include various departments, subsidiaries, and responsible personnel within the company [1]. Group 2: Organizational Structure and Responsibilities - The company has established an audit department as the internal audit body, responsible for supervising business activities, risk management, internal controls, and financial information [2]. - The audit department is independent and should not be under the leadership of the finance department [2]. - The audit department reports to the board of directors and is supervised by the audit committee [2]. Group 3: Scope and Authority - The audit department conducts audits on financial plans, cost plans, financial activities, major economic contracts, internal control systems, and compliance with financial regulations [4][5]. - The audit department has the authority to request necessary documents, attend relevant meetings, and propose temporary measures against violations of financial regulations [5]. Group 4: Audit Types and Methods - The main types of audits include financial audits and special audits focusing on the legality and effectiveness of economic activities [9]. - Audit methods include document review, observation, inquiry, and analytical review to gather sufficient and relevant evidence [6]. Group 5: Reporting and Evaluation - The audit department must report at least quarterly to the board or audit committee on the execution of the audit plan and any issues found [6]. - The audit committee oversees the audit department and ensures that internal control evaluations are conducted regularly [7][8]. Group 6: Confidentiality and Personnel - The audit department must maintain confidentiality and not disclose internal audit information to unauthorized parties [12]. - Audit personnel are required to possess necessary professional knowledge and adhere to ethical standards in their work [20][24].

陕西盘龙药业集团股份有限公司中小投资者单独计票机制实施细则 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 为进一步落实国家有关加强资本市场中小投资者合法权益保护工作 意见，充分保障中小投资者依法行使权利，完善公司股东会表决相关重大事项 时对中小投资者的投票情况进行单独计票的流程及披露机制，根据有关法律、 法规和规范性文件，结合陕西盘龙药业集团股份有限公司（以下简称"公司"） 实际情况，制定本细则。 （一）利润分配方案、资本公积金转增股本方案、弥补亏损方案； （二）修改公司章程中涉及中小投资者利益的条款； （三）发行公司证券； （四）重大资产重组； （五）公司合并、分立、解散、清算； （六）重大关联交易； （七）股权激励计划； （八）重大对外投资、对外担保、对外提供财务资助； （九）选举和更换非由职工代表担任的董事，决定有关董事、高级管理人 员的报酬事项； 第二条 本细则所称中小投资者是指股东会股权登记日除公司董事、高级管 理人员以及单独或者合计持有公司5%以上（含本数）股份的股东以外的其他股 东。 第二章 单独计票的适用范围 第三条 股东会审议影响中小投资者利益的重大事项时，对 ...

Core Viewpoint - The document outlines the information disclosure management system of Shaanxi Panlong Pharmaceutical Group Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of investors and comply with relevant laws and regulations. Group 1: General Principles - The company aims to ensure that all disclosed information is true, accurate, complete, timely, and fair, without any false records or misleading statements [3][4][5] - Information disclosure obligations apply to the company, its directors, senior management, and other relevant parties, ensuring that significant events affecting stock prices are disclosed promptly [2][6] Group 2: Disclosure Procedures - The company must disclose periodic reports, including annual and interim reports, which should be audited by qualified accounting firms [10][21] - The disclosure of significant events must occur immediately when they are known, especially if they could impact stock prices [18][22] Group 3: Responsibilities and Oversight - The board of directors is responsible for establishing and implementing the information disclosure management system, ensuring compliance and timely disclosures [15][19] - The audit committee and independent directors are tasked with supervising the implementation of the disclosure system and addressing any deficiencies [8][29] Group 4: Specific Disclosure Requirements - The company must disclose information regarding major shareholders, changes in control, and any significant legal proceedings that could affect its financial status [20][34] - Any changes in the company's financial performance or significant operational events must be reported to maintain transparency with investors [14][16]

General Principles - The company establishes a management system for the deferral and exemption of information disclosure to regulate the behavior of the company and other information disclosure obligors, enhance information disclosure supervision, and protect investors' legitimate rights and interests [1][2] - The company and other information disclosure obligors must disclose information truthfully, accurately, completely, timely, and fairly, and must not abuse deferral or exemption to evade disclosure obligations or mislead investors [1][2] Scope and Management of Deferral and Exemption - The company can exempt disclosure if there is sufficient evidence that the information involves state secrets or other matters that may violate state confidentiality regulations [2][3] - The company has an obligation to protect state secrets and must not leak them through any form of information disclosure or interaction with investors [2][3] - Information involving commercial secrets can be deferred or exempted if it meets certain conditions, such as being core technology information that could lead to unfair competition if disclosed [2][3] Internal Review Procedures - The company’s board secretary is responsible for organizing and coordinating the deferral and exemption of information disclosure, with the board office handling daily operations [5] - If a deferral or exemption application is not approved by the board secretary or the chairman, the company must disclose the information in accordance with securities regulatory requirements [5] Reporting and Documentation - The company must register details of the deferral or exemption, including the type of documents involved and the internal review procedures [4][5] - After the annual, semi-annual, or quarterly reports are announced, the company must submit relevant registration materials regarding deferrals or exemptions to the local securities regulatory bureau and stock exchange within ten days [4][5]

（2025 年 月） 陕西盘龙药业集团股份有限公司募集资金管理制度 陕西盘龙药业集团股份有限公司 第一章 总则 第一条 为规范陕西盘龙药业集团股份有限公司（以下简称"公司"）募集 资金管理，提高募集资金使用效率，根据《中华人民共和国公司法》、 《中华人民 共和国证券法》 （以下简称"证券法"）、 《首次公开发行股票注册管理办法》、 《深 《深圳证券交易所上市公司监管指引 1 号—主板上 圳证券交易所股票上市规则》、 市公司规范运作》《上市公司募集资金监管规则》、《陕西盘龙药业集团股份有限 公司章程》 （以下简称"公司章程"）以及其他有关法律、法规的规定，并结合公 司实际情况，制定本制度。 第二条 本管理制度所称募集资金是指公司通过向不特定对象发行证券（包 括首次公开发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转 换公司债券、发行权证等）以及向特定对象发行股票向投资者募集并用于特定用 途的资金。 发行股票、可转换债券或其他证券的募集资金到位后，公司应及时办理验资 手续，由具有证券从业资格的会计师事务所出具验资报告。 第三条 公司董事会应当对募集资金投资项目的可行性进行充分论证，确信 投资项目具有较 ...

陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司 章程 二〇二五年 月 （以下简称"公司法"）、 《中华人民共和国证券法》 （以下简称"证 券法"）、 《上市公司证券发行注册管理办法（2025 年修订）》、 陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司 章程 第一章 总则 第一条 为维护陕西盘龙药业集团股份有限公司（以下简称"公司"）及 其股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共 和国公司法》 第七条 公司为永久存续的股份有限公司。 《上市公司章程指 引》、 《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》、 《中国共产党章程》和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关法律、行政法规设立的股份有 限公司。 公司采取发起设立的方式设立；在陕西省市场监督管理局注册登记，取得营 业执照，营业执照号为 91610000223472005U。 第三条 公司于 2017 年 10 月 20 日经中国证券监督管理委员会（以下简称 "中国证监会"）批准，首次向社会公众发行人民币普通股 2,167 ...

General Principles - The management system for online voting at the shareholders' meeting of Shaanxi Panlong Pharmaceutical Group Co., Ltd. is established to standardize online voting behavior, facilitate shareholders in exercising their voting rights, and protect investors' legal rights [2][3] - The online voting system includes the Shenzhen Stock Exchange trading system and an internet voting system [2][3] Voting Rights and Procedures - All shareholders registered on the equity registration date have the right to vote through the online voting system, and the same shares can only choose one voting method [3][4] - The company must provide a secure, economical, and convenient online voting system for shareholders during the shareholders' meeting [3][6] Preparation for Online Voting - The company must clearly state voting codes, proposal numbers, voting time, and other relevant information in the notice of the shareholders' meeting [5][6] - The company is required to complete the review of voting information by the trading day following the equity registration date [6][7] Voting Methods - Voting through the Shenzhen Stock Exchange trading system occurs during the trading hours of the shareholders' meeting [8][9] - The internet voting system is available from 9:15 AM on the day of the shareholders' meeting until 3:00 PM on the same day [10][11] Voting Results and Counting Rules - Shareholders who vote multiple times through the online voting system will be considered present at the meeting, and their votes will be counted based on the number of shares held [13][14] - The company must provide a voting platform that prioritizes online voting for significant matters affecting minority investors [14][15] Special Voting Provisions - For cumulative voting proposals, shareholders have voting rights equivalent to the number of candidates to be elected [17][18] - The company must ensure that votes from shareholders with special voting rights are counted according to the original voting data [21][22] Finalization of Voting Results - After the on-site voting concludes, the company will obtain online voting data and ensure compliance in confirming the voting results [24][25] - The company is responsible for the service fees associated with online voting [26][27]